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Abstract
AIM: To determine the efficacy of calcium supple-
mentation in reducing the recurrence of colorectal 
adenomas. 
METHODS: We conducted a systematic review and 
meta-analysis of published studies. We searched 
PubMed, Scopus, the Cochrane Library, the WHO 
International Clinical Trials Registry Platform, and the 
ClinicalTrials.gov website, through December 2015. 
Randomized, placebo-controlled trials assessing 
supplemental calcium intake for the prevention of 
recurrence of adenomas were eligible for inclusion. 
Two reviewers independently selected studies based 
on predefined criteria, extracted data and outcomes 
(recurrence of colorectal adenomas, and advanced 
or “high-risk” adenomas), and rated each trial’s risk-
of-bias. Between-study heterogeneity was assessed, 
and pooled risk ratio (RR) estimates with their 95% 
confidence intervals (95%CI) were calculated using 
fixed- and random-effects models. To express the 
treatment effect in clinical terms, we calculated the 
number needed to treat (NNT) to prevent one adenoma 
recurrence. We also assessed the quality of evidence 
using GRADE.
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represents the third most common malignancy, and 
the fourth most common cause of cancer deaths 
globally, accounting for 1.35 million new cases and 0.7 
million deaths annually[4]. 
The magnitude of the colorectal cancer problem, 
and the failure of advanced disease chemotherapy to 
effect significant reductions in the respective mortality 
rates, indicate that an intensive approach to the 
prevention of this disease is necessary. Accordingly, 
research on chemopreventive agents for colorectal 
cancer has received much attention over the last 30 
years. Among several promising compounds (including 
vitamins A, C, and E, folate and other B vitamins, 
aspirin, sulindac and other non-aspirin non-steroidal 
anti-inflammatory drugs, statins, bisphosphonates, 
selenium, and fiber)[5-16], calcium has also been 
studied. It was proposed by Newmark et al[17] that 
calcium binds bile acids in the bowel lumen, inhibiting 
their well-known proliferative and carcinogenic effects. 
In addition, calcium has demonstrated a direct 
antiproliferative effect on cells, as well as promoting 
cellular differentiation and death (apoptosis)[18]. 
Evidence from epidemiologic studies also suggests that 
higher calcium intake may reduce the risk of colorectal 
cancer[19].
Most colorectal tumors develop from adenomas 
arising from the lining of the intestine. Progression - 
described as the adenoma-cancer (or polyp-cancer) 
sequence - is characterized by morphological and 
histological changes[20]. For instance, a small tubular 
adenoma acquires villoglandular characteristics as it 
grows. On the molecular level, the adenoma-cancer 
sequence reflects an accumulation of genomic defects. 
Generally, a single adenoma has a risk of progressing 
into neoplasia of 0.25% per year[21], depending on its 
size, location, histological type, and the presence of 
dysplasia. 
The standard treatment for colorectal adenomas is 
endoscopic resection that interrupts the progression to 
invasive disease[22]. However, even after polypectomy, 
rates of adenoma recurrence may be up to 50% 
within 3 years of follow-up[23,24]. That is why research 
on colorectal cancer prevention has often focused on 
prevention of recurrent adenomas. Assuming that 
the effects of chemopreventive agents on adenomas 
reflect those on cancer, this endpoint provides a 
convenient surrogate for the study of colorectal cancer 
prevention[25,26]. 
Contrary to expectations, the recent randomized 
placebo-controlled trial published by Baron et al[27] 
showed that daily supplementation with 1200 mg 
of calcium did not significantly reduce the risk of 
colorectal adenomas over a time period of 3 to 5 years. 
In view of earlier promising clinical trial data[28,29], we 
sought to obtain a comprehensive snapshot of the 
existing evidence on the clinical efficacy of calcium 
supplementation for the prevention of colorectal 
adenomas. Therefore, we carried out an updated 
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RESULTS: Four randomized, placebo-controlled trials 
met the eligibility criteria and were included. Daily 
doses of elemental calcium ranged from 1200 to 2000 
mg, while the duration of treatment and follow-up 
of participants ranged from 36 to 60 mo. Synthesis 
of intention-to-treat data, for participants who had 
undergone follow-up colonoscopies, indicated a modest 
protective effect of calcium in prevention of adenomas 
(fixed-effects, RR = 0.89, 95%CI: 0.82-0.96; random-
effects, RR = 0.87, 95%CI: 0.77-0.98; high quality of 
evidence). The NNT was 20 (95%CI: 12-61) to prevent 
one colorectal adenoma recurrence within a period of 3 
to 5 years. On the other hand, the association between 
calcium treatment and advanced adenomas did not 
reach statistical significance (fixed-effects, RR = 0.92, 
95%CI: 0.75-1.13; random-effects, RR = 0.92, 95%CI: 
0.71-1.18; moderate quality of evidence). 
CONCLUSION: Our results suggest a modest chemo-
preventive effect of calcium supplements against 
recurrent colorectal adenomas over a period of 36 to 
60 mo. Further research is warranted. 
Key words: Calcium; Colorectal adenoma; Recurrence; 
Cancer chemoprevention; Colorectal cancer; Systematic 
review; Meta-analysis; Polyp
© The author(s) 2016. Published by Baishideng Publishing 
Group Inc. All rights reserved.
Core tip: To assess the efficacy of calcium supple-
mentation in reducing the recurrence of colorectal 
adenomas, we conducted a systematic review and 
meta-analysis of randomized, placebo-controlled trials. 
We found a modest protective effect of calcium in 
prevention of adenomas (fixed-effects, RR = 0.89, 
95%CI: 0.82-0.96; random-effects, RR = 0.87, 95%CI: 
0.77-0.98; high quality of evidence). On the other 
hand, the association between calcium treatment 
and advanced (“high-risk”) colorectal adenomas was 
not statistically significant (fixed-effects, RR = 0.92, 
95%CI: 0.75-1.13; random-effects, RR = 0.92, 95%CI: 
0.71-1.18; moderate quality of evidence). Further 
targeted research is warranted. 
Bonovas S, Fiorino G, Lytras T, Malesci A, Danese S. Calcium 
supplementation for the prevention of colorectal adenomas: A 
systematic review and meta-analysis of randomized controlled 
trials. World J Gastroenterol 2016; 22(18): 4594-4603  Available 
from: URL: http://www.wjgnet.com/1007-9327/full/v22/
i18/4594.htm  DOI: http://dx.doi.org/10.3748/wjg.v22.i18.4594
INTRODUCTION
Colorectal cancer is a tumour resulting from a complex 
interaction between inherited susceptibility and 
environmental factors, as demonstrated by genetic, 
experimental, and epidemiological studies[1-3]. It 
systematic review and meta-analysis of randomized 
controlled trials (RCTs) published in the peer-reviewed 
literature.
MATERIALS AND METHODS
Data sources and search strategy
To identify the studies of interest, we systematically 
searched the PubMed and Scopus bibliographic 
databases from their inception to 15 December 2015 
(date of final search). Search terms included: “calcium” 
combined with “adenoma” or “polyp”. The search 
was limited to RCTs and human studies. No language 
restrictions were applied. 
We also searched the Cochrane Library for any 
recently published systematic review on the subject, 
the WHO International Clinical Trials Registry Platform, 
and the ClinicalTrials.gov website, for completed but 
unpublished studies. 
Two authors (Bonovas S and Lytras T) indepen-
dently reviewed titles and abstracts to identify studies 
for inclusion. The full texts of the selected articles 
were carefully examined for eligibility, and their 
reference lists (as well as those of relevant systematic 
reviews[30-33]) were also investigated to identify any 
studies missed by the electronic database search. 
Selection criteria 
Studies were eligible for inclusion if they were rando-
mized, placebo-controlled trials assessing supplemental 
calcium intake for the prevention of recurrent colorectal 
adenomas. All studies had to include follow-up 
evaluation (i.e., endoscopy) to confirm the presence 
or absence of adenomas. If the results of a study were 
reported in multiple publications and/or at multiple 
time-points, we selected the most updated publication 
and extracted the data for the maximum follow-up time 
reported, as long as it remained a randomized trial and 
fully reported the outcomes of interest. 
Studies were excluded if they were observational; 
did not report (or provided insufficient data to 
calculate) the outcomes of interest; or evaluated multi-
interventional therapies, in which the effect of calcium 
treatment could not be separated out. We did not 
apply restrictions on eligibility according to dosage, or 
duration of calcium supplementation. 
Types of outcomes and data extraction 
We analyzed the following two outcomes: (1) recurrence 
of colorectal adenomas (at least one adenoma detected 
during follow-up colonoscopies); and (2) recurrence of 
advanced or “high-risk” adenomas (defined as those 
that have a diameter ≥ 10 mm, villous or tubulovillous 
features, or severe dysplasia). 
Data extraction was independently undertaken by 
two authors (Bonovas S and Lytras T) using a prede-
signed form. The following information was extracted 
from each study: first author, journal and year of 
publication, study design and duration, number and 
characteristics of participants, intervention parameters, 
and number of subjects with the outcomes of interest 
reported for the intervention and control groups. 
Disagreements were resolved via consensus, referring 
back to the original articles.
Assessment of risk of bias
We assessed the risk of bias (RoB) in included studies 
using the Cochrane Collaboration’s tool[34], which 
addresses the following key-domains: sequence gene-
ration; allocation concealment; blinding; incomplete 
outcome data; selective outcome reporting; and other 
sources of bias, such as extreme baseline imbalances in 
prognostic factors, etc. These items were considered for 
RoB assessment and were classified as “adequate” (low 
RoB), “inadequate” (high RoB), or “unclear” (uncertain 
RoB). 
Studies reporting adequate procedures in all 
domains were classified as “low RoB”, studies with 
inadequate procedures in at least one domain were 
classified as “high RoB”, and those with unclear 
procedures in one or more domains were classified as 
“uncertain RoB”. Discrepancies among reviewers were 
discussed and agreement was reached by consensus. 
Data synthesis and analysis
The risk ratio (RR) was used to measure treatment 
effects. Study-level RRs along with their 95%CI were 
calculated using intention-to-treat data for study 
participants who completed the follow-up evaluation 
(i.e., follow-up colonoscopies). 
Meta-analyses were performed twice, assuming 
a fixed-effects model (Mantel-Haenszel approach[35]) 
and a random-effects model (DerSimonian-Laird 
approach[36]). Under a fixed-effects model, we assume 
that the included studies share a common true effect, 
and the pooled effect is an estimate of the common 
effect size. Under a random-effects model, we assume 
that the true effects vary between the studies, and 
the pooled effect is a weighted average of the effects 
reported in the different studies. The random-effects 
model often leads to broader confidence intervals (i.e., 
it is a more conservative approach)[37]. 
The between-study heterogeneity was evaluated 
using the Cochran’s Q test[38], with a 0.10 level of 
significance, and the I-squared metric[39], which 
describes the percentage of variation across studies that 
is due to heterogeneity rather than chance. I-squared 
values of less than 25%, 25%-50%, or higher than 
50% indicate low, moderate, or high heterogeneity, 
respectively[40]. 
Publication bias was not assessed, because the 
relevant statistical tests lack power when the number 
of included studies is limited[41].
To express the treatment effect in clinical terms, we 
calculated the number needed to treat (NNT) to prevent 
one adenoma recurrence using the Mantel-Haenszel 
4596 May 14, 2016|Volume 22|Issue 18|WJG|www.wjgnet.com
Bonovas S et al . Calcium for the prevention of colorectal adenomas
randomized studies of calcium supplementation 
met the eligibility criteria and were included: (1) the 
Vitamin D/Calcium Polyp Prevention Study[27,46]; (2) 
the Southwest Oncology Group (SWOG) Calcium 
Chemoprevention Pilot Study[47,48]; (3) the European 
Cancer Prevention Organisation (ECP) Calcium Fibre 
Polyp Prevention Study[28,49,50]; and (4) the Calcium 
Polyp Prevention Study[29,51,52].
They were multicenter, randomized, placebo-
controlled trials of supplementation with calcium for 
the prevention of colorectal adenomas. Daily doses 
of elemental calcium ranged from 1200 to 2000 mg, 
while the duration of treatment and follow-up of 
patients ranged from 36 to 60 mo. A summary of the 
trials’ characteristics is given in Table 1.
Patients underwent endoscopy at baseline; 
subsequent colonoscopies were then undertaken 
to assess adenoma recurrence during the follow-
up. The studies differ in that the SWOG Calcium 
Chemoprevention Pilot Study[47,48] recruited patients 
with completely resected colorectal cancer, while all 
the other studies included participants with colorectal 
adenomas removed before enrollment. All studies 
reported the number of subjects with adenomas (and 
advanced adenomas) identified during the follow-up 
fixed-effects risk difference (risk in the placebo group 
minus risk in the calcium group), in cases in which a 
statistically significant RR was detected. The NNT is the 
inverse of this risk difference. 
The quality of evidence (confidence in the synthesized 
effect estimates) was assessed using GRADE (Grading 
of Recommendations Assessment, Development and 
Evaluation)[42]. 
For all statistical analyses, we used the R software[43], 
version 3.2.2, and the “meta” package for R[44], version 
4.3-0. All P-values are two-tailed. For all tests (except 
for heterogeneity), a P-value less than 0.05 indicates 
statistical significance. 
Our study was performed in accordance with the 
Cochrane Handbook for intervention reviews[41], and 
the PRISMA (Preferred Reporting Items for Systematic 
Reviews and Meta-analyses) statement[45]. 
The study did not involve any experiment on humans 
or animals, thus an ethical approval was not required. 
RESULTS
Search results 
A summary of the literature search and selection 
process is shown in Figure 1 (Flow diagram). Four 
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Figure 1  Summary of the evidence search and selection process (flow diagram). RCTs: Randomized controlled trials.
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endoscopies; thus, we were able to conduct a post 
hoc analysis of these clinical trials, calculate RRs for 
the outcomes of interest, and incorporate them in the 
meta-analyses. 
Another two clinical trials were identified, but did 
not meet the eligibility criteria, and were excluded. 
The first study - included in two previous systematic 
reviews[31,32] - examined a mixed intervention consi-
sting of calcium, β-carotene, vitamin C, vitamin E, and 
selenium, compared with placebo[53,54]. The second 
clinical trial, which was evaluating a combination 
treatment of aspirin, calcitriol, and calcium, compared 
with placebo, was terminated early because no 
positive tendency was shown in a preplanned interim 
analysis[55,56]. In both studies, the effect of calcium 
could not be separated out; thus, they were not 
included in the evidence synthesis. 
Risk of bias in included studies 
The Vitamin D/Calcium Polyp Prevention Study[27,46], 
the ECP Calcium Fibre Polyp Prevention Study[28,49,50], 
and the Calcium Polyp Prevention Study[29,51,52], were 
judged to be at low RoB: their allocation sequences 
appeared to be adequately generated and concealed; 
patients and staff were masked; participants excluded 
from the analyses (those who had not undergone 
follow-up colonoscopy) were balanced in numbers and 
reasons across intervention groups; and the outcomes 
of interest for this review were fully reported. 
The SWOG Calcium Chemoprevention Pilot Study[47,48] 
was considered to have uncertain RoB, because 
information was insufficient to permit judgement about 
the sequence generation process, the method used to 
conceal allocation, and attritions/exclusions. 
Quality assessment items are presented in Figure 2. 
Results of quantitative synthesis 
Recurrence of colorectal adenomas: Intention-
to-treat data for 2984 participants, who underwent 
follow-up colonoscopies, were analyzed. Each one of 
the four included trials reported a lower recurrence 
rate of colorectal adenomas in the calcium group, as 
compared to the placebo group; however, the results 
only from two studies (the Calcium Polyp Prevention 
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Table 1  Randomized, double-blind, placebo-controlled trials of calcium supplementation for prevention of colorectal adenomas
Study or subgroup1 Participants 
randomized
Mean age (yr) Women Follow-up (mo) Amount of elemental calcium 
supplemented (mg/d)
Vitamin D/Calcium Polyp Prevention Study[27] 1675 59 15% 36 or 60 1200
SWOG Calcium Chemoprevention Pilot Study[47]   220  682 37% 60 1800
ECP Calcium Fibre Polyp Prevention Study[28]   439 59 37% 36 2000
Calcium Polyp Prevention Study[51,52]   930 61 28% 48 1200
1For the Vitamin D/Calcium Polyp Prevention Study, only a subgroup was taken into account in the analysis; 2Median value. ECP: European Cancer 
Prevention Organisation; SWOG: Southwest Oncology Group.
Vitamin D/Calcium polyp prevention study
SWOG Calcium chemoprevention pilot study
ECP Calcium fibre polyp prevention study
Calcium polyp prevention study
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Figure 2  Risk-of-bias assessment for the studies included in the meta-analysis. Green (+): Low risk-of-bias; Yellow (?): Unclear risk-of-bias. ECP: European 
Cancer Prevention Organisation; SWOG: Southwest Oncology Group.
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Study[29,51,52] and the SWOG Calcium Chemoprevention 
Pilot Study[47,48]) were statistically significant. The 
overall recurrence rate, on all four RCTs, was 41.1% in 
calcium groups and 46.2% in placebo groups, over a 
treatment and follow-up period of 3 to 5 years. 
We found a statistically significant modest 
protective effect (about 10%-15% risk reduction) of 
calcium supplements in the prevention of colorectal 
adenomas, both under the assumption of a fixed-
effects model (RR = 0.89, 95%CI: 0.82-0.96) and a 
random-effects model (RR = 0.87, 95%CI: 0.77-0.98). 
The RRs with their 95%CIs for the individual studies, 
and the pooled results, are shown in Figure 3. The 
Cochran’s Q test had a P-value of 0.18 and the 
corresponding I-squared value was 39%, indicating 
moderate heterogeneity between the studies. 
For patients treated with calcium supplements in 
the included trials, the NNT was 20 (95%CI: 12-61) to 
prevent one colorectal adenoma recurrence within a 
period of 3 to 5 years. 
Recurrence of advanced (high-risk) adenomas: 
We analyzed data for 2998 participants, who com-
pleted their follow-up evaluations (colonoscopies). 
None of the studies reported statistically significant 
results for advanced adenomas. Their overall occu-
rrence, on all four RCTs, was 10.4% in calcium groups 
and 11.3% in placebo groups. 
In meta-analysis, the association between calcium 
treatment and advanced adenomas did not reach 
statistical significance, either assuming a fixed-effects 
model (RR = 0.92, 95%CI: 0.75-1.13) or a random-
effects model (RR = 0.92, 95%CI: 0.71-1.18). The 
RRs with their 95%CIs for the individual studies, 
and the pooled results, are presented in Figure 4. 
The Cochran’s Q test had a P-value of 0.30 and the 
corresponding I-squared value was 17%, indicating 
low heterogeneity between the studies. 
Quality of the evidence
Using the GRADE approach[42], our confidence in the 
synthesized evidence is “high” for the first outcome 
(adenomas), but “moderate” for the second one 
(advanced adenomas), for the following reasons: 
(1) the data were derived from RCTs, which are 
considered as the gold standard for assessing drugs[57]; 
(2) the synthesized effect estimates are precise for 
adenomas, but imprecise for advanced adenomas; (3) 
heterogeneity is low-to-moderate across studies; and 
(4) publication bias is not likely. 
A high quality of evidence means that “we are very 
confident that the true effect lies close to that of the 
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Figure 3  Forest plot for adenomas: results from individual studies and meta-analysis. For the analysis we used intention-to-treat data for patients who 
underwent follow-up evaluation (follow-up colonoscopies). ECP: European Cancer Prevention Organisation; SWOG: Southwest Oncology Group; n: Number of 
subjects with at least one adenoma detected during the follow-up evaluation; N: Number of subjects who underwent follow-up evaluation; RR: Risk ratio.
0.75     1.0         1.5
Randomized controlled trials Calcium Placebo                  Risk ratio RR 95%CI Weight Weight
n N n N (fixed) (random)
Vitamin D/Calcium polyp prevention study 345   762 362   761 0.95 0.85-1.06 52.5% 43.5%
SWOG Calcium chemoprevention pilot study   42     95   62     99 0.71 0.54-0.93   8.8% 14.9%
ECP Calcium fibre polyp prevention study   28   176   36   178 0.79 0.50-1.23   5.2%   6.4%
Calcium polyp prevention study 196   454 232   459 0.85 0.74-0.98 33.5% 35.2%
1487 1497
Fixed effect model 0.89 0.82-0.96 100.0% -
Random effects models 0.87 0.77-0.98 - 100.0%
Heterogeneity: I 2 = 38.7%, Tau2 = 0.0055, P  = 0.1798
0.5        1.0          2.0
Randomized controlled trials Calcium Placebo          Risk ratio RR 95%CI Weight Weight
n N n N (fixed) (random)
Vitamin D/Calcium polyp prevention study 81   773 77   764 1.04 0.77-1.40 45.6% 45.1%
SWOG Calcium chemoprevention pilot study 11     95 11     99 1.04 0.47-2.29   6.3%   9.0%
ECP Calcium fibre polyp prevention study 10   176   7   178 1.44 0.56-3.71   4.1%   6.4%
Calcium polyp prevention study 54   454 75   459 0.73 0.53-1.01 43.9% 39.6%
1498 1500
Fixed effect model 0.92 0.75-1.13 100.0% -
Random effects models 0.92 0.72-1.18 - 100.0%
Heterogeneity: I 2 = 17.4%, Tau2 = 0.0116, P  = 0.3043
Figure 4  Forest plot for advanced adenomas: results from individual studies and meta-analysis. For the analysis we used intention-to-treat data for patients 
who underwent follow-up evaluation (follow-up colonoscopies). ECP: European Cancer Prevention Organisation; SWOG: Southwest Oncology Group; n: Number of 
subjects with at least one adenoma detected during the follow-up evaluation; N: Number of subjects who underwent follow-up evaluation; RR: Risk ratio.
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estimate of the effect”, while a moderate quality of 
evidence means that “we are moderately confident in 
the effect estimate. The true effect is likely to be close 
to the estimate of the effect, but there is a possibility 
that it is substantially different”[58]. 
A summary of findings and strength of evidence is 
shown in Table 2. 
DISCUSSION
Chemoprevention is a promising area of cancer 
research focusing on prevention of malignancies 
through pharmacological, biological, and nutritional 
interventions[59]. As first defined by Sporn[60], cancer 
chemoprevention uses natural, synthetic, or biologic 
agents to reverse, suppress, or prevent either the initial 
phase of carcinogenesis or the progression of malignant 
cells to cancer[61-65]. Regarding chemoprevention of 
colorectal cancer, several studies suggest that calcium 
may have chemopreventive potential[66-72]. Our know-
ledge on the underlying mechanism is incomplete. It 
has been proposed that calcium may protect against 
neoplasia in the large bowel by binding bile and 
fatty acids, thus decreasing their proliferative and 
carcinogenic effects on colonic epithelial cells[17]. 
Meta-analysis is a statistical methodology for 
combining the findings from independent studies[73]. 
We undertook this systematic review and meta-
analysis to assess and synthesize the existing evidence 
on the efficacy of calcium supplements in prevention 
of colorectal adenomas. 
In the recent literature, we have identified three 
systematic reviews with meta-analyses of RCTs 
examining the efficacy of calcium supplementation for 
the prevention of colorectal adenomas[31-33]. Carroll 
et al[31] and Shaukat et al[32] performed similar three-
trial meta-analyses including the ECP Calcium Fibre 
Polyp Prevention Study[28,49,50], the Calcium Polyp 
Prevention Study[29,51,52], as well as the Hofstad et al[53,54] 
study that examined a mixed intervention consisting 
of calcium, β-carotene, vitamin C, vitamin E, and 
selenium, compared with placebo. Both meta-analyses 
found a significant 20% risk reduction associated with 
calcium. On the other hand, the third meta-analysis by 
Weingarten et al[33] reported a larger protective effect for 
calcium (OR = 0.74, 95%CI: 0.58-0.95) including only 
the ECP Calcium Fibre Polyp Prevention Study[28,49,50] 
and the Calcium Polyp Prevention Study[29,51,52], and 
excluding the Hofstad et al[53,54] study because of the 
use of antioxidants as a co-intervention. However, 
Weingarten et al[33] used the numbers of randomized 
subjects, rather than the numbers of subjects who 
completed the follow-up evaluation (colonoscopy), as 
the denominator in the analysis. This approach assumes 
that none of the subjects lost to follow-up experienced 
the outcomes[74,75]; however, this assumption does not 
appear to be valid. 
In our study, a rigorous and extensive literature 
search was conducted; four eligible randomized 
trials were identified (the Vitamin D/Calcium 
Polyp Prevention Study[27,46], the SWOG Calcium 
Chemoprevention Pilot Study[47,48], the ECP Calcium 
Fibre Polyp Prevention Study[28,49,50], and the Calcium 
Polyp Prevention Study[29,51,52]); two further trials 
were excluded (the Hofstad et al[53,54] study and 
the Pommergaard et al[55] study[56]) because they 
evaluated multi-interventional treatments where 
the effect of calcium could not be separated out; 
data extraction was carefully undertaken by two 
independent investigators; and the evidence was 
synthesized using appropriate statistical techniques. 
Our results indicate a modest chemopreventive effect 
of calcium supplements against colorectal adenomas 
(approximately 10%-15% risk reduction; high quality 
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Table 2  Summary of findings
Illustrative comparative risks (95%CI)
Assumed risk Corresponding risk
Placebo Calcium
Recurrence of adenomas 
(follow-up: 3 to 5 yr)
462 per 1000 411 per 1000 Relative effect (95%CI): RR = 0.89 (0.82-0.96)
(379 to 444) No. of patients with follow-up evaluation: 2984
No. of RCTs: 4
Quality of evidence (GRADE): ++++ (high)
Advanced adenomas 
(follow-up: 3 to 5 yr)
113 per 1000 104 per 1000 Relative effect (95%CI): RR = 0.92 (0.75-1.13)
(85 to 128) No. of patients with follow-up evaluation: 2998
No. of RCTs: 4
Quality of evidence (GRADE): +++- (moderate)
(1) the basis for calculating the assumed risk is the overall event rate across the trial groups receiving placebo; (2) the corresponding risk (calcium group) 
is based on the assumed risk and the relative effect estimate (risk ratio); (3) the relative effect estimate and its 95%CI come from a Mantel-Haenszel 
fixed-effects meta-analytic model; and (4) the overall quality of evidence is judged as “high” for recurrence of adenomas, and “moderate” for advanced 
adenomas. A high quality of evidence means that “we are very confident that the true effect lies close to that of the estimate of the effect”, while a moderate 
quality of evidence means that “we are moderately confident in the effect estimate. The true effect is likely to be close to the estimate of the effect, but 
there is a possibility that it is substantially different”[58]. Population: Patients with colorectal adenomas removed before enrollment. Intervention: Calcium 
supplementation (1200-2000 mg/d) to prevent recurrence of adenomas. Comparison: Placebo. RR: Risk ratio; GRADE; Grading of Recommendations 
Assessment, Development and Evaluation; RCTs: Randomized controlled trials.
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of evidence). However, this effect was not statistically 
significant for the advanced (high-risk) adenomas 
(imprecise pooled effect estimates; moderate quality 
of evidence). These findings extend the results of the 
primary trials and have important implications for 
future research.
The strengths of this systematic review should be 
weighed against a number of limitations. Firstly, the 
number of available studies was limited. Secondly, a 
colorectal adenoma typically requires 10-15 years to 
evolve into clinically invasive cancer[76]. Therefore, we 
did not examine whether calcium supplementation 
affects the progression of adenomas into invasive 
cancer. To address this question, studies with longer 
durations of treatment and follow-up are necessary. 
Thirdly, we could not analyze whether the dose of 
calcium affected the results; however, the dose range 
was relatively narrow in the included trials (range: 
1200-2000 mg of elemental calcium daily). 
Despite these limitations, our study is the most 
up-to-date meta-analysis on the topic and adheres 
to the recommended PRISMA reporting standards. 
Calcium does not appear to strongly reduce the 
risk of adenomas; however, there is high quality 
evidence suggesting a modest overall risk reduction, 
which might be a composite of an effect of calcium 
supplements in some populations (e.g., the non-
obese[27]) and some adenoma types (e.g., the right-
colon adenomas[28]), and lack of effect in others. 
Therefore, we consider that the recent negative results 
published by Baron et al[27] is not the end of the road 
for calcium as a potential chemopreventive agent 
against colorectal carcinoma; rather a new research 
approach is warranted. There is good reason to focus 
again on basic research, and perform clinical and 
epidemiologic studies to answer questions related 
to dosing and duration of treatment, and identify 
populations for whom calcium might be particularly 
beneficial for prevention of adenomas and colorectal 
cancer. 
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Colorectal cancer is the 3rd most common malignancy and the 4th most common 
cause of cancer deaths globally, with 1.35 million new cases and 0.7 million 
deaths annually. Most colorectal malignancies develop from adenomas arising 
from the lining of the intestine. That is why research on colorectal cancer 
prevention has often focused on prevention of recurrent adenomas.
Research frontiers
It has been suggested that calcium binds bile acids in the bowel lumen, 
inhibiting their well-known proliferative and carcinogenic effects. Calcium has 
also demonstrated a direct antiproliferative effect on cells, as well as promoting 
cellular differentiation and apoptosis. 
Innovations and breakthroughs
Contrary to expectations, the recent randomized controlled trial published by 
Baron et al showed that daily supplementation with 1200 mg of calcium did 
not significantly reduce the risk of colorectal adenomas over a period of 3 to 5 
years. In view of earlier promising clinical data, the authors sought to obtain a 
comprehensive picture of the evidence by conducting a systematic review and 
meta-analysis of randomized controlled trials.
Applications
The results show a modest chemopreventive effect of calcium supplements 
against recurrent colorectal adenomas. Further clinical and epidemiological 
research is warranted to answer questions related to dosing and duration of 
treatment, and identify populations for whom calcium might be particularly 
beneficial.
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Meta-analysis is a statistical methodology for combining the findings from 
independent studies.
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paper on secondary adenoma prevention in the colon. The authors give a 
comprehensive view of an important clinical topic.
REFERENCES
1 Willett W. The search for the causes of breast and colon cancer. 
Nature 1989; 338: 389-394 [PMID: 2648156 DOI: 10.1038/338389a0]
2 Reddy B, Engle A, Katsifis S, Simi B, Bartram HP, Perrino P, 
Mahan C. Biochemical epidemiology of colon cancer: effect of 
types of dietary fiber on fecal mutagens, acid, and neutral sterols 
in healthy subjects. Cancer Res 1989; 49: 4629-4635 [PMID: 
2545348]
3 Potter JD. Reconciling the epidemiology, physiology, and 
molecular biology of colon cancer. JAMA 1992; 268: 1573-1577 
[PMID: 1518112 DOI: 10.1001/jama.1992.03490120087033]
4 Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo 
M, Parkin DM, Forman D, Bray F. Cancer incidence and mortality 
worldwide: sources, methods and major patterns in GLOBOCAN 
2012. Int J Cancer 2015; 136: E359-E386 [PMID: 25220842 DOI: 
10.1002/ijc.29210]
5 Greenberg ER, Baron jA, Tosteson TD, Freeman DH, Beck 
GJ, Bond JH, Colacchio TA, Coller JA, Frankl HD, Haile RW. A 
clinical trial of antioxidant vitamins to prevent colorectal adenoma. 
Polyp Prevention Study Group. N Engl J Med 1994; 331: 141-147 
[PMID: 8008027 DOI: 10.1056/NEJM199407213310301]
6 Cole BF, Baron jA, Sandler RS, Haile RW, Ahnen Dj, Bresalier 
RS, McKeown-Eyssen G, Summers RW, Rothstein RI, Burke CA, 
Snover DC, Church TR, Allen jI, Robertson Dj, Beck Gj, Bond 
jH, Byers T, Mandel jS, Mott LA, Pearson LH, Barry EL, Rees 
JR, Marcon N, Saibil F, Ueland PM, Greenberg ER. Folic acid for 
the prevention of colorectal adenomas: a randomized clinical trial. 
JAMA 2007; 297: 2351-2359 [PMID: 17551129 DOI: 10.1001/
jama.297.21.2351]
7 Song Y, Manson jE, Lee IM, Cook NR, Paul L, Selhub j, 
Giovannucci E, Zhang SM. Effect of combined folic acid, vitamin 
B(6), and vitamin B(12) on colorectal adenoma. J Natl Cancer 
Inst 2012; 104: 1562-1575 [PMID: 23066166 DOI: 10.1093/jnci/
djs370]
8 Baron JA, Cole BF, Sandler RS, Haile RW, Ahnen D, Bresalier 
R, McKeown-Eyssen G, Summers RW, Rothstein R, Burke CA, 
Snover DC, Church TR, Allen jI, Beach M, Beck Gj, Bond jH, 
Byers T, Greenberg ER, Mandel jS, Marcon N, Mott LA, Pearson 
L, Saibil F, van Stolk RU. A randomized trial of aspirin to prevent 
colorectal adenomas. N Engl J Med 2003; 348: 891-899 [PMID: 
12621133 DOI: 10.1056/NEJMoa021735]
9 Hull MA, Sandell AC, Montgomery AA, Logan RF, Clifford GM, 
4601 May 14, 2016|Volume 22|Issue 18|WJG|www.wjgnet.com
 COMMENTS
Bonovas S et al . Calcium for the prevention of colorectal adenomas
Rees CJ, Loadman PM, Whitham D. A randomized controlled trial 
of eicosapentaenoic acid and/or aspirin for colorectal adenoma 
prevention during colonoscopic surveillance in the NHS Bowel 
Cancer Screening Programme (The seAFOod Polyp Prevention 
Trial): study protocol for a randomized controlled trial. Trials 2013; 
14: 237 [PMID: 23895505 DOI: 10.1186/1745-6215-14-237]
10 Matsuhashi N, Nakajima A, Fukushima Y, Yazaki Y, Oka T. 
Effects of sulindac on sporadic colorectal adenomatous polyps. Gut 
1997; 40: 344-349 [PMID: 9135523 DOI: 10.1136/gut.40.3.344]
11 Meyskens FL, McLaren CE, Pelot D, Fujikawa-Brooks S, Carpenter 
PM, Hawk E, Kelloff G, Lawson Mj, Kidao j, McCracken j, Albers 
CG, Ahnen Dj, Turgeon DK, Goldschmid S, Lance P, Hagedorn CH, 
Gillen DL, Gerner EW. Difluoromethylornithine plus sulindac for the 
prevention of sporadic colorectal adenomas: a randomized placebo-
controlled, double-blind trial. Cancer Prev Res (Phila) 2008; 1: 
32-38 [PMID: 18841250 DOI: 10.1158/1940-6207.CAPR-08-0042]
12 Thompson P, Roe Dj, Fales L, Buckmeier j, Wang F, Hamilton 
SR, Bhattacharyya A, Green S, Hsu CH, Chow HH, Ahnen Dj, 
Boland CR, Heigh RI, Fay DE, Martinez ME, jacobs E, Ashbeck 
EL, Alberts DS, Lance P. Design and baseline characteristics 
of participants in a phase III randomized trial of celecoxib and 
selenium for colorectal adenoma prevention. Cancer Prev Res (Phila) 
2012; 5: 1381-1393 [PMID: 23060037 DOI: 10.1158/1940-6207.
CAPR-12-0204]
13 Lytras T, Nikolopoulos G, Bonovas S. Statins and the risk of 
colorectal cancer: an updated systematic review and meta-analysis 
of 40 studies. World J Gastroenterol 2014; 20: 1858-1870 [PMID: 
24587664 DOI: 10.3748/wjg.v20.i7.1858]
14 Bonovas S, Nikolopoulos G, Bagos P. Bisphosphonate use and 
risk of colorectal cancer: a systematic review and meta-analysis. 
Br J Clin Pharmacol 2013; 76: 329-337 [PMID: 23594375 DOI: 
10.1111/bcp.12135]
15 Bonovas S, Filioussi K, Flordellis CS, Sitaras NM. Statins and the 
risk of colorectal cancer: a meta-analysis of 18 studies involving 
more than 1.5 million patients. J Clin Oncol 2007; 25: 3462-3468 
[PMID: 17687150 DOI: 10.1200/JCO.2007.10.8936]
16 Bonovas S. Statins: do they have a potential role in cancer prevention 
and modifying cancer-related outcomes? Drugs 2014; 74: 1841-1848 
[PMID: 25288321 DOI: 10.1007/s40265-014-0309-2]
17 Newmark HL, Wargovich MJ, Bruce WR. Colon cancer and 
dietary fat, phosphate, and calcium: a hypothesis. J Natl Cancer 
Inst 1984; 72: 1323-1325 [PMID: 6587152 DOI: 10.1093/
jnci/72.6.1323]
18 Lamprecht SA, Lipkin M. Chemoprevention of colon cancer 
by calcium, vitamin D and folate: molecular mechanisms. Nat 
Rev Cancer 2003; 3: 601-614 [PMID: 12894248 DOI: 10.1038/
nrc1144]
19 Huncharek M, Muscat J, Kupelnick B. Colorectal cancer risk 
and dietary intake of calcium, vitamin D, and dairy products: a 
meta-analysis of 26,335 cases from 60 observational studies. Nutr 
Cancer 2009; 61: 47-69 [PMID: 19116875 DOI: 10.1080/0163558
0802395733]
20 Hoff G, Vatn MH. Colonic adenoma: natural history. Dig Dis 
1991; 9: 61-69 [PMID: 2036733 DOI: 10.1159/000171293]
21 Eide TJ. Risk of colorectal cancer in adenoma-bearing individuals 
within a defined population. Int J Cancer 1986; 38: 173-176 [PMID: 
3733258]
22 Winawer SJ, Zauber AG, Ho MN, O’Brien Mj, Gottlieb LS, 
Sternberg SS, Waye JD, Schapiro M, Bond JH, Panish JF. Prevention 
of colorectal cancer by colonoscopic polypectomy. The National 
Polyp Study Workgroup. N Engl J Med 1993; 329: 1977-1981 
[PMID: 8247072 DOI: 10.1056/NEJM199312303292701]
23 Neugut AI, jacobson jS, Ahsan H, Santos j, Garbowski GC, 
Forde KA, Treat MR, Waye J. Incidence and recurrence rates of 
colorectal adenomas: a prospective study. Gastroenterology 1995; 
108: 402-408 [PMID: 7835580 DOI: 10.1016/0016-5085(95)9006
6-7]
24 Brand L, Munding j, Pox CP, Ziebarth W, Reiser M, Hüppe 
D, Schmiegel W, Reinacher-Schick A, Tannapfel A. ß-Catenin, 
Cox-2 and p53 immunostaining in colorectal adenomas to predict 
recurrence after endoscopic polypectomy. Int J Colorectal Dis 
2013; 28: 1091-1098 [PMID: 23516071 DOI: 10.1007/s00384-
013-1667-z]
25 Bonovas S, Tsantes A, Drosos T, Sitaras NM. Cancer chemopre-
vention: a summary of the current evidence. Anticancer Res 2008; 
28: 1857-1866 [PMID: 18630472]
26 Peipins LA, Sandler RS. Epidemiology of colorectal adenomas. 
Epidemiol Rev 1994; 16: 273-297 [PMID: 7713180]
27 Baron JA, Barry EL, Mott LA, Rees jR, Sandler RS, Snover DC, 
Bostick RM, Ivanova A, Cole BF, Ahnen Dj, Beck Gj, Bresalier 
RS, Burke CA, Church TR, Cruz-Correa M, Figueiredo jC, 
Goodman M, Kim AS, Robertson Dj, Rothstein R, Shaukat A, 
Seabrook ME, Summers RW. A Trial of Calcium and Vitamin D for 
the Prevention of Colorectal Adenomas. N Engl J Med 2015; 373: 
1519-1530 [PMID: 26465985 DOI: 10.1056/NEJMoa1500409]
28 Bonithon-Kopp C, Kronborg O, Giacosa A, Räth U, Faivre J. 
Calcium and fibre supplementation in prevention of colorectal 
adenoma recurrence: a randomised intervention trial. European Cancer 
Prevention Organisation Study Group. Lancet 2000; 356: 1300-1306 
[PMID: 11073017 DOI: 10.1016/S0140-6736(00)02813-0]
29 Baron JA, Beach M, Mandel jS, van Stolk RU, Haile RW, Sandler 
RS, Rothstein R, Summers RW, Snover DC, Beck Gj, Bond 
JH, Greenberg ER. Calcium supplements for the prevention of 
colorectal adenomas. Calcium Polyp Prevention Study Group. N 
Engl J Med 1999; 340: 101-107 [PMID: 9887161 DOI: 10.1056/
NEJM199901143400204]
30 Keum N, Lee DH, Greenwood DC, Zhang X, Giovannucci EL. 
Calcium intake and colorectal adenoma risk: dose-response meta-
analysis of prospective observational studies. Int J Cancer 2015; 
136: 1680-1687 [PMID: 25156950 DOI: 10.1002/ijc.29164]
31 Carroll C, Cooper K, Papaioannou D, Hind D, Pilgrim H, 
Tappenden P. Supplemental calcium in the chemoprevention 
of colorectal cancer: a systematic review and meta-analysis. 
Clin Ther 2010; 32: 789-803 [PMID: 20685491 DOI: 10.1016/
j.clinthera.2010.04.024]
32 Shaukat A, Scouras N, Schünemann HJ. Role of supplemental 
calcium in the recurrence of colorectal adenomas: a metaanalysis 
of randomized controlled trials. Am J Gastroenterol 2005; 100: 
390-394 [PMID: 15667497 DOI: 10.1111/j.1572-0241.2005.41220.
x]
33 Weingarten MA, Zalmanovici A, Yaphe J. Dietary calcium 
supplementation for preventing colorectal cancer and adenomatous 
polyps. Cochrane Database Syst Rev 2008; (1): CD003548 [PMID: 
18254022 DOI: 10.1002/14651858.CD003548.pub4]
34 Higgins JP, Altman DG, Gøtzsche PC, jüni P, Moher D, Oxman 
AD, Savovic J, Schulz KF, Weeks L, Sterne JA. The Cochrane 
Collaboration’s tool for assessing risk of bias in randomised trials. 
BMJ 2011; 343: d5928 [PMID: 22008217 DOI: 10.1136/bmj.
d5928]
35 Mantel N, Haenszel W. Statistical aspects of the analysis of data 
from retrospective studies of disease. J Natl Cancer Inst 1959; 22: 
719-748 [PMID: 13655060]
36 DerSimonian R, Laird N. Meta-analysis in clinical trials. Control 
Clin Trials 1986; 7: 177-188 [PMID: 3802833]
37 Petitti DB. Statistical methods in meta-analysis. In: Petitti DB. 
Meta-Analysis, Decision Analysis, and Cost-Effectiveness 
Analysis. New York: Oxford University Press, 1999
38 Cochran WG. The combination of estimates from different 
experiments. Biometrics 1954; 810: 101-129
39 Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-
analysis. Stat Med 2002; 21: 1539-1558 [PMID: 12111919 DOI: 
10.1002/sim.1186]
40 Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring 
inconsistency in meta-analyses. BMJ 2003; 327: 557-560 [PMID: 
12958120 DOI: 10.1136/bmj.327.7414.557]
41 Higgins JPT, Green S, editors. Cochrane handbook for systematic 
reviews of interventions. Version 5.1.0. The Cochrane Collaboration, 
2011. Available from: URL: http://www.cochrane-handbook.org
42 Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-
Coello P, Schünemann HJ. GRADE: an emerging consensus 
4602 May 14, 2016|Volume 22|Issue 18|WJG|www.wjgnet.com
Bonovas S et al . Calcium for the prevention of colorectal adenomas
on rating quality of evidence and strength of recommendations. 
BMJ 2008; 336: 924-926 [PMID: 18436948 DOI: 10.1136/
bmj.39489.470347.AD]
43 R Development Core Team. R: A Language and Environment for 
Statistical Computing. Vienna, Austria: R Foundation for Statistical 
Computing, 2014
44 Schwarzer G. Meta: An R package for meta-analysis. R News 
2007; 7: 40-45
45 Liberati A, Altman DG, Tetzlaff j, Mulrow C, Gøtzsche PC, 
Ioannidis JP, Clarke M, Devereaux PJ, Kleijnen J, Moher D. 
The PRISMA statement for reporting systematic reviews and 
meta-analyses of studies that evaluate health care interventions: 
explanation and elaboration. PLoS Med 2009; 6: e1000100 [PMID: 
19621070 DOI: 10.1371/journal.pmed.1000100]
46 Vitamin D/Calcium Polyp Prevention Study. Available from: URL: 
https://clinicaltrials.gov/ct2/show/NCT00153816
47 Chu DZ, Hussey MA, Alberts DS, Meyskens FL, Fenoglio-Preiser 
CM, Rivkin SE, Mills GM, Giguere jK, Blanke CD, Goodman 
GE. Colorectal Chemoprevention Pilot Study (SWOG-9041), 
randomized and placebo controlled: the importance of multiple 
luminal lesions. Clin Colorectal Cancer 2011; 10: 310-316 [PMID: 
21782524 DOI: 10.1016/j.clcc.2011.06.005]
48 Chu DZ, Chansky K, Alberts DS, Meyskens FL, Fenoglio-Preiser 
CM, Rivkin SE, Mills GM, Giguere jK, Goodman GE, Abbruzzese 
JL, Lippman SM. Adenoma recurrences after resection of 
colorectal carcinoma: results from the Southwest Oncology Group 
9041 calcium chemoprevention pilot study. Ann Surg Oncol 2003; 
10: 870-875 [PMID: 14527904 DOI: 10.1245/ASO.2003.03.037]
49 Faivre J, Couillault C, Kronborg O, Rath U, Giacosa A, De Oliveira 
H, Obrador T, O’Morain O. Chemoprevention of metachronous 
adenomas of the large bowel: design and interim results of a 
randomized trial of calcium and fibre. ECP Colon Group. Eur J 
Cancer Prev 1997; 6: 132-138 [PMID: 9237061]
50 Faivre J, Doyon F, Boutron MC. The ECP calcium fibre polyp 
prevention study. The ECP Colon Group. Eur J Cancer Prev 1991; 
1 Suppl 2: 83-89 [PMID: 1668817]
51 Baron JA, Beach M, Mandel jS, van Stolk RU, Haile RW, Sandler 
RS, Rothstein R, Summers RW, Snover DC, Beck Gj, Frankl H, 
Pearson L, Bond JH, Greenberg ER. Calcium supplements and 
colorectal adenomas. Polyp Prevention Study Group. Ann N Y 
Acad Sci 1999; 889: 138-145 [PMID: 10668490]
52 Wallace K, Baron jA, Cole BF, Sandler RS, Karagas MR, Beach 
MA, Haile RW, Burke CA, Pearson LH, Mandel jS, Rothstein 
R, Snover DC. Effect of calcium supplementation on the risk of 
large bowel polyps. J Natl Cancer Inst 2004; 96: 921-925 [PMID: 
15199111 DOI: 10.1093/jnci/djh165]
53 Hofstad B, Almendingen K, Vatn M, Andersen SN, Owen 
RW, Larsen S, Osnes M. Growth and recurrence of colorectal 
polyps: a double-blind 3-year intervention with calcium and 
antioxidants. Digestion 1998; 59: 148-156 [PMID: 9586828 DOI: 
10.1159/000007480]
54 Hofstad B, Vatn M, Hoff G, Larsen S, Osnes M. Growth of 
colorectal polyps: design of a prospective, randomized, placebo-
controlled intervention study in patients with colorectal polyps. 
Eur J Cancer Prev 1992; 1: 415-422 [PMID: 1463996]
55 Pommergaard HC, Burcharth J, Rosenberg J, Raskov H. Aspirin, 
Calcitriol, and Calcium Do Not Prevent Adenoma Recurrence 
in a Randomized Controlled Trial. Gastroenterology 2016; 150: 
114-122.e4 [PMID: 26404953 DOI: 10.1053/j.gastro.2015.09.010]
56 A clinical trial evaluating the efficacy and safety of a combination 
treatment administered over three years in patients at risk of 
experiencing recurrence of colorectal adenomas. Available from: 
URL: https://clinicaltrials.gov/ct2/show/NCT00486512
57 Chassin MR, Galvin RW. The urgent need to improve health care 
quality. Institute of Medicine National Roundtable on Health Care 
Quality. JAMA 1998; 280: 1000-1005 [PMID: 9749483 DOI: 
10.1001/jama.280.11.1000]
58 Balshem H, Helfand M, Schünemann Hj, Oxman AD, Kunz R, 
Brozek j, Vist GE, Falck-Ytter Y, Meerpohl j, Norris S, Guyatt 
GH. GRADE guidelines: 3. Rating the quality of evidence. J Clin 
Epidemiol 2011; 64: 401-406 [PMID: 21208779 DOI: 10.1016/
j.jclinepi.2010.07.015]
59 Bonovas S. Cancer chemoprevention: progress and perspectives. 
Curr Drug Targets 2011; 12: 1871-1873 [PMID: 21158713 DOI: 
10.2174/138945011798184137]
60 Sporn MB. Approaches to prevention of epithelial cancer during 
the preneoplastic period. Cancer Res 1976; 36: 2699-2702 [PMID: 
1277177]
61 Greenwald P. Cancer chemoprevention. BMJ 2002; 324: 714-718 
[PMID: 11909790 DOI: 10.1136/bmj.324.7339.714]
62 Wattenberg LW. Chemoprevention of cancer. Cancer Res 1985; 
45: 1-8 [PMID: 3880665]
63 Lippman SM, Benner SE, Hong WK. Cancer chemoprevention. J 
Clin Oncol 1994; 12: 851-873 [PMID: 8151328]
64 Sporn MB, Suh N. Chemoprevention of cancer. Carcinogenesis 
2000; 21: 525-530 [PMID: 10688873 DOI: 10.1093/carcin/21.3.525]
65 Sporn MB, Suh N. Chemoprevention: an essential approach to 
controlling cancer. Nat Rev Cancer 2002; 2: 537-543 [PMID: 
12094240 DOI: 10.1038/nrc844]
66 Giovannucci E. Modifiable risk factors for colon cancer. 
Gastroenterol Clin North Am 2002; 31: 925-943 [PMID: 12489270 
DOI: 10.1016/S0889-8553(02)00057-2]
67 Lipkin M. Early development of cancer chemoprevention clinical 
trials: studies of dietary calcium as a chemopreventive agent for 
human subjects. Eur J Cancer Prev 2002; 11 Suppl 2: S65-S70 
[PMID: 12570337]
68 Slattery ML. Diet, lifestyle, and colon cancer. Semin Gastrointest 
Dis 2000; 11: 142-146 [PMID: 10950460]
69 Lipkin M, Reddy B, Newmark H, Lamprecht SA. Dietary factors 
in human colorectal cancer. Annu Rev Nutr 1999; 19: 545-586 
[PMID: 10448536 DOI: 10.1146/annurev.nutr.19.1.545]
70 Martínez ME, Willett WC. Calcium, vitamin D, and colorectal 
cancer: a review of the epidemiologic evidence. Cancer Epidemiol 
Biomarkers Prev 1998; 7: 163-168 [PMID: 9488592]
71 Lipkin M, Newmark H. Calcium and the prevention of colon 
cancer. J Cell Biochem Suppl 1995; 22: 65-73 [PMID: 8538212 
DOI: 10.1002/jcb.240590810]
72 Pence BC. Role of calcium in colon cancer prevention: experimental 
and clinical studies. Mutat Res 1993; 290: 87-95 [PMID: 7694103 
DOI: 10.1016/0027-5107(93)90036-F]
73 Nikolopoulos GK, Bagos PG, Bonovas S. Developing the 
evidence base for cancer chemoprevention: use of meta-analysis. 
Curr Drug Targets 2011; 12: 1989-1997 [PMID: 21158703 DOI: 
10.2174/138945011798184191]
74 Montori VM, Guyatt GH. Intention-to-treat principle. CMAJ 
2001; 165: 1339-1341 [PMID: 11760981]
75 Hollis S, Campbell F. What is meant by intention to treat analysis? 
Survey of published randomised controlled trials. BMJ 1999; 319: 
670-674 [PMID: 10480822 DOI: 10.1136/bmj.319.7211.670]
76 Jänne PA, Mayer RJ. Chemoprevention of colorectal cancer. 
N Engl J Med 2000; 342: 1960-1968 [PMID: 10874065 DOI: 
10.1056/NEJM200006293422606]
P- Reviewer: Hoensch HP, Lee jE    S- Editor: Gong ZM 
L- Editor: A    E- Editor: Ma S
4603 May 14, 2016|Volume 22|Issue 18|WJG|www.wjgnet.com
Bonovas S et al . Calcium for the prevention of colorectal adenomas
                                      © 2016 Baishideng Publishing Group Inc. All rights reserved.
Published by Baishideng Publishing Group Inc
8226 Regency Drive, Pleasanton, CA 94588, USA
Telephone: +1-925-223-8242
Fax: +1-925-223-8243
E-mail: bpgoffice@wjgnet.com
Help Desk: http://www.wjgnet.com/esps/helpdesk.aspx
http://www.wjgnet.com
I S S N  1 0  0 7  -   9  3 2  7
9   7 7 1 0  07   9 3 2 0 45
1  8
